Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron transdermal patch vs oral granisetron for chemotherapy‑induced nausea and vomiting
CTR20130844Phase 3Completed
- Sponsor
- Strakan International
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granisetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Strakan International. Primary endpoint: Complete control of chemotherapy-induced nausea and vomiting from start of chemotherapy to 24 hours after end of last chemotherapy dose. Started Aug 2014; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20130844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130844.